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Previous studies have shown that EAE can be elicited by the adoptive transfer of either
IFN-c-producing (Th1) or IL-17-producing (Th17) myelin-specific CD41 T-cell lines. Para-
doxically, mice deficient in either IFN-c or IL-17 remain susceptible to EAE following
immunization with myelin antigens in CFA. These observations raise questions about the
redundancy of IFN-c and IL-17 in autoimmune demyelinating disease mediated by a
diverse, polyclonal population of autoreactive T cells. In this study, we show that an
atypical form of EAE, induced in C57BL/6 mice by the adoptive transfer of IFN-c-deficient
effector T cells, required IL-17 signaling for the development of brainstem infiltrates. In
contrast, classical EAE, characterized by predominant spinal cord inflammation, occurred
in the combined absence of IFN-c and IL-17 signaling, but was dependent on GM-CSF and
CXCR2. Our findings contribute to a growing body of data, indicating that individual
cytokines vary in their importance across different models of CNS autoimmunity.
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Introduction
EAE is an inflammatory demyelinating disease of the CNS that
shares clinical and histopathological characteristics with MS. EAE
is induced in laboratory animals by active immunization with
myelin antigens or by the adoptive transfer of myelin-specific
CD41 T cells. EAE was historically viewed as a prototypical Th1-
driven autoimmune disorder until it was demonstrated that mice
deficient in key components of the Th1 pathway, such as IFN-g,
the b2 chain of the IL-12 receptor, or the p35 subunit of IL-12,
remain fully susceptible to disease [1–3]. In fact, mice with IFN-g
deficiencies exhibit a severe, atypical form of inflammatory
demyelination characterized by neutrophil-rich infiltrates in the
brainstem [4, 5].
Th17 cells were subsequently implicated in EAE pathogenesis,
following the demonstration that mice deficient in IL-23
(a monokine that stabilizes and expands Th17 cells) fail to
succumb to the disease and that in several experimental para-
digms, IL-23 stimulation directly confers encephalitogenicity to
myelin-specific T cells [6, 7]. Furthermore, Th17 cells accumulate
in EAE and MS lesions, and IL-17 is expressed at high levels in
circulating leukocytes and cerebrospinal fluid mononuclear cells
from patients with active MS [8, 9]. However, analogous to the
situation with IFN-g, neither deficiency nor neutralization of
IL-17 completely prevents EAE [10, 11]. Conversely, over-
expression of IL-17A in myelin-specific T cells did not enhance
their encephalitogenicity [12]. Finally, T-bet-deficient mice are
resistant to EAE despite mounting a robust Th17 response against
myelin antigens [1, 13, 14].
A number of recent studies have revisited the relative
importance of Th1 and Th17 cells in inflammatory demyelina-
tion. Th1-polarized myelin-specific T-cell lines were found to be
more potent than Th17-polarized lines of the same reactivity in
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the adoptive transfer of EAE [15]. These Th17 cells induced a
relatively mild and delayed form of EAE, and did so only once
they acquired the ability to secrete IFN-g in host mice. Similar
observations have been made in a Th17-mediated model of
diabetes [16].
Collectively, the above data suggest that both Th1- and
Th17-polarized T-cell lines are capable of initiating EAE.
Paradoxically, however, neither IFN-g nor IL-17 is required for
disease induction following active immunization of susceptible
mice with myelin antigens in CFA. This raises the question of
whether one effector cytokine compensates for the absence
of the other in the context of a diverse, polyclonal autoimmune
response. In this article, we show that classical EAE, characterized
by an ascending paralysis, can occur independent of the
activities of both IFN-g and IL-17. In this setting, GM-CSF and
CXCR2 play critical roles in the pathogenic process. In
contrast, atypical EAE, with prominent brainstem signs, is
IL-17 dependent. Our findings challenge traditional notions
regarding the association between the encephalitogenic potential
of autoreactive T cells and their production of individual
Th1 and/or Th17-related cytokines. They further expand
the spectrum of autoimmune diseases to include those
mediated by an IFN-g/IL-17-independent, GM-CSF-dependent
pathway.
Results
IL-12-polarized Th1 cells induce conventional EAE
independent of IL-17A/F signaling
Myelin oligodendrocyte glycoprotein (MOG)35–55/CFA-
primed CD41 T cells were cultured for 96 h with antigen alone
or with antigen plus IL-12, IFN-g and neutralizing antibody
to IL-4. The IL-12-stimulated cells produced large quantities of
IFN-g, but no detectable IL-17 or IL-4, upon secondary in vitro
challenge with MOG peptide (Fig. 1A). In addition, they
upregulated T-bet mRNA approximately 16-fold over the level
expressed in T cells harvested from the same mice that were
stimulated under neutral conditions (Fig. 1B). Only IL-12-
stimulated T cells induced EAE, manifested as an ascending
paralysis (Fig. 1C and data not shown). Disease was not
dependent on IL-17 since it was induced in 100% of IL-17
receptor deficient as well as WT mice with comparable kinetics
and severity (Fig. 1C).
In order to assess the role of IFN-g in the encephalitogenicity
of the transferred T cells, the above experiments were repeated
using IFN-g-deficient donors. IL-12-stimulated, MOG-specific
IFN-g/ CD41 T cells produced no detectable IL-4 upon
secondary challenge (Fig. 1A). A small percentage of these cells
Figure 1. Induction of atypical EAE by IL-12-polarized, IFN-g-deficient T cells is IL-17-dependent. WT or IFN-g/ MOG35–55/CFA-primed
T cells were cultured with antigen under conditions favorable to the generation of Th1 cells (IL-12, IFN-g, and aIL-4) for 4 days. (A) CD41 T cells were
isolated after 4-day in vitro polarization and restimulated in ELISPOT assays for IL-4, IL-17, and IFN-g with naı̈ve T-depleted splenocytes 750 mg/mL
MOG35–55. Background counts with media alone were subtracted. (B) RNA was isolated from purified WT or IFN-g
/ CD41 T cells after polarization
with IL-12 (left) or from WT CD41 T cells after polarization with IL-23 (right). Transcription factor expression was assessed by real-time RT-PCR.
Data were normalized to GAPDH and are shown as fold expression over the levels measured in CD41 T cells that were stimulated with MOG35–55
alone. (C) MOG-specific WT or IFN-g/ CD41 T cells were transferred to either WT or IL-17RA/ mice. The recipients were scored on a daily basis
according to the conventional EAE scale (five to seven mice per group). (D) MOG-specific IFN-g/ CD41 T cells were transferred to WT mice. The
recipients were scored according to the atypical EAE scale (four mice per group). (E) IL-17RA/mice were injected with MOG-specific IFN-g/ CD41
T cells and treated with a neutralizing antibody to IFN-g or isotype-matched rat IgG. All data shown are representative of two to four independent
experiments.
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produced IL-17. T-bet mRNA was significantly upregulated after
96 h of stimulation, but to levels 50% lower than those induced in
WT cells under the same Th1 polarizing conditions (Fig. 1B).
Gata3 and RORgt were expressed at a fraction of the levels
measured in unpolarized T cells. Consistent with the previous
reports [4, 5], IL-12-stimulated, MOG-specific IFN-g/ CD41
T cells triggered an atypical form of EAE in WT hosts, char-
acterized by gait imbalance and neutrophil-rich brainstem
infiltrates (Fig. 1D and Fig. 2E, left panel).
Atypical EAE is IL-17RA dependent
Next, we investigated whether IL-17 assumes a compensatory
role in EAE initiated by IFN-g-deficient donor cells. CD41
T cells were harvested from MOG35–55 immunized IFN-g-deficient
mice, cultured with antigen and IL-12, and adoptively transferred
into IL-17RA-deficient hosts. IL-17RA-deficient mice
succumbed to EAE, but the disease reverted to the conventional
clinical phenotype of an ascending paralysis (Fig. 1C). Treatment
of IL-17RA-deficient adoptive transfer recipients with a neutraliz-
ing antibody against IFN-g had no impact on EAE severity or
incidence, demonstrating that host-derived IFN-g was not
responsible for the classical EAE phenotype (Fig. 1E). Based on
these data, we concluded that brainstem, but not spinal
cord, inflammation is dependent on IL-17 signaling in host
cells. Our findings corroborate the previous observations
that a high ratio of IL-17 to IFN-g-producing cells in the lymph
nodes of myelin immunized mice is predictive of brainstem
inflammation and that IL-17 neutralization prevents atypical EAE
[17].
IL-12-polarized, IFN-c-deficient cells fail to accumulate
in the brains of IL-17RA-null mice
Histopathological studies revealed a similar pattern and degree of
spinal cord inflammation in WT and IL-17RA-deficient
recipients of IL-12-stimulated WT T cells (Fig. 2A and B). As
expected, brainstem infiltrates were prominent in WT
mice that developed atypical EAE, following the transfer of
IL-12-polarized IFN-g-deficient effector cells (Fig. 2E, left panel).
Despite the predominance of brainstem signs exhibited by these
mice, they developed large spinal cord infiltrates that actually
extended deeper into the spinal cord parenchyma than the
infiltrates in the paraparetic mice that had been injected with WT
effector cells (Fig. 2C). IL-12-polarized IFN-g/ T cells induced
large parenchymal infiltrates in the spinal cords, but not the
brainstems, of IL-17RA-deficient recipients (Fig. 2D and E, right
panel). Collectively, these data indicate that brainstem parench-
ymal inflammation is predicated on two conditions: (i) IL-17
signaling pathways are intact and (ii) donor cells are unable to
produce IFN-g. In contrast, extensive spinal cord infiltration
occurs in the setting of IFN-g deficiency irrespective of IL-17
signaling.
IFN-c-deficient effector T cells induce CNS infiltrates
that are neutrophil-rich and macrophage-poor
CD11b1 MHC class II1 cells comprised a significant component of
the CNS infiltrates induced by WT effector cells. The absolute
number and percentage of CNS CD11b1 class II1 cells was
comparable between WT and IL-17RA-deficient hosts (Fig. 3A,
Figure 2. IL-12-polarized IFN-g-deficient T cells fail to induce brain
inflammation in the absence of IL-17A/F signaling. MOG35–55/CFA-
primed lymph node cells from WT or IFN-g/ mice were cultured with
peptide under Th1-polarizing conditions for 4 days, and transferred to
WT or IL-17RA/ mice. (A–D) Spinal cord and (E) brainstem tissue was
fixed at peak EAE, sectioned, and stained with hematoxylin and eosin.
(A, B) Spinal cord sections from (A) WT or (B) IL-17RA/ mice injected
with WT Th1 cells. (C, D) Spinal cord sections from (C) WT or
(D) IL-17RA/ mice injected with IL-12-polarized IFN-g/ cells. Left
panels: 4 magnification, bar 5 100mm; right panels: 40 , bar 5 20mm.
(E) Brainstem sections from WT (left) or IL-17RA/ (right) hosts
following transfer of IL-12-polarized IFN-g/ effector T cells. Brain-
stem sections were taken at 2 magnification, bar 5 500 mm. Inset
image was taken at 40 magnification and is 40 mm wide. Representa-
tive sections are shown from two or more independent experiments.
& 2010 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.eji-journal.eu
Eur. J. Immunol. 2010. 40: 2340–2348Mark A. Kroenke et al.2342
Table 1). The presence of MHC class II1 cells correlated with high
levels of CD74 (invariant chain) mRNA in the spinal cord at peak
disease (Table 2). It is worth noting that CD74 facilitates
trafficking of mature class II molecules to the cell surface [18,
19]. The CD11b1 class II1 subset was less prevalent in CNS
infiltrates induced by IFN-g/ effectors (Fig. 3A and Table 1).
CNS-infiltrating cells from mice injected with IFN-g/ effec-
tor cells contained a prominent subpopulation of neutrophils,
constituting 40–50% of infiltrating cells, irrespective of IL-17
receptor expression (Fig. 3B). In contrast, the percentage of
neutrophils in infiltrates induced by WT effector cells ranged
between 2 and 25%. The absolute number of neutrophils was
significantly lower in IL-17RA/ than WT recipients of either WT
or IFN-g/ effector cells, respectively (Table 1). Reduced
neutrophil numbers in the CNS of IL-17RA/ hosts correlated
with relatively low expression of CXCL1 and CXCL2 (Table 2 and
data not shown). Hence, the capacity of effector T cells to
produce IFN-g is the dominant factor determining the cellular
composition of the CNS infiltrates they trigger; IL-17 impacts the
cellular composition of infiltrates induced by IFN-g sufficient cells
(whereby it facilitates neutrophil enrichment).
There was no consistent difference in the percentage or
absolute number of spinal cord-infiltrating CD41 cells or B2201
cells between the four experimental groups (Fig. 3C and Table 1).
CD81 cells and NK1.11 cells were not detected in the CNS of any
experimental group (data not shown).
GM-CSF is required in EAE induced by the transfer of
IFN-c/ effectors into IL-17RA/ mice
As shown earlier, IL-12-polarized IFN-g/ CD41 cells produce
small quantities of IL-17 and no detectable IL-4 or IFN-g upon
reactivation with MOG35–55 (Fig. 1A). Hence, they are neither
classical Th1 nor Th17 cells, yet they remain highly encephalito-
genic (Fig. 1C–E). In order to identify the factors that IL-12-
polarized IFN-g/ cells employ to mediate inflammatory demye-
lination, we performed targeted PCR arrays on RNA isolated from
Figure 3. IFN-g/ effector cells induce neutrophil-rich infiltrates irrespective of IL-17 signaling. Mononuclear cells were isolated from spinal cord
tissue at peak disease and analyzed by flow cytometry. IL-12-polarized WT or IFN-g/ effector cells were injected into WT or IL-17RA/ hosts as
indicated in the figure. Plots show (A) MHC class II versus CD11b, (B) 7/4 versus Ly6G (gated on CD11b1 cells), or (C) CD4 versus B220. The data shown
are representative of at least two independent experiments.
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spinal cords of IL-17RA/ recipients at peak disease. CCL22 and
CCL17 were among the molecules that were upregulated above
levels in the naı̈ve CNS (Table 2). CCL22 and CCL17 are
downstream of the Th2 cytokine IL-13 in delayed type hypersensi-
tivity reactions and in the formation of schistosomal granulomas
[20]. However, administration of a neutralizing antiserum against
IL-13 did not suppress the induction of EAE in our model (data not
shown). Furthermore, IL-13, IL-4, and IL-5 transcripts were not
detected either in the IL-12-polarized, IFN-g/ effector cells or in
the spinal cords of host mice with EAE (data not shown). Taken
together, these data indicate that EAE mediated by the non-Th1/
Th17 effector cells is not Th2 driven.
IL-1 was dramatically upregulated in the CNS of mice with
IL-17/IFN-g-independent EAE (Table 2). IL-1R antagonism was
previously shown to ameliorate EAE induced by active immuniza-
tion of C57BL/6 WT mice with MOG35–55 [21]. IL-1b is an effective
inducer of CXCL1/2 in the CNS [22], suggesting that it might be
involved in the recruitment of neutrophils to the CNS in our model.
Nonetheless, treatment of IL-17RA-deficient mice with the IL-1R
antagonist Anakinra (KineretTM) failed to suppress EAE transferred
by IL-12-polarized IFN-g/ MOG-specific T cells (Fig. 4A). In
contrast, we reproduced the earlier studies demonstrating that
Anakinra prevents MOG-specific T-cell priming and the develop-
ment of neurological deficits when given prophylactically to
actively immunized mice (our unpublished observations). This
suggests that the importance of IL-1 in EAE is model dependent.
Finally, GM-CSF transcripts were expressed at high levels in
the spinal cords of IL-17RA/ hosts (Table 2). IL-12-polarized
IFN-g-deficient lymph node cells secreted large quantities of
GM-CSF protein in response to antigenic challenge in vitro
(Fig. 4B). Intracellular staining revealed that CD41 T cells were
the major source of GM-CSF protein in CNS infiltrates (Fig. 4C).
In order to determine whether GM-CSF is critical for the
manifestation of conventional EAE following adoptive transfer of
IL-12-polarized IFN-g-deficient cells, we treated IL-17RA-deficient
adoptive transfer recipients with neutralizing antibody to GM-CSF
or rat IgG isotype control. The mice treated with monoclonal
antibody to GM-CSF were completely protected from EAE and
remained healthy after the cessation of therapy (Fig. 4D). There-
fore, production of GM-CSF by infiltrating CD41 T cells promotes
induction of EAE in the absence of IFN-g and IL-17A/F signals.
EAE is CXCR2 dependent in the absence of CD4-derived
IFN-c and IL-17A/F signaling
We found that neutrophils constitute 40–50% of the spinal cord-
infiltrating cells in the non-Th1/Th17 model (Fig. 3B). In order to
assess the requirement of neutrophil trafficking to the CNS for the
manifestation of clinical EAE, we treated IL-17RA-deficient mice
with a neutrophil-depleting CXCR2 anti-serum, following adoptive
transfer of IL-12-modulated MOG-specific IFN-g/ cells. Flow
Table 1. Absolute cell numbers per spinal cord
Wt-Wt Wt-IL-17R/ IFN-g/-Wt IFN-g/-IL-17R/
Total cells/corda) 3.2105 (8.7104) 3.2105 (12.9104) 2.5105 (2.3104) 1.6105 (2.9104)
CD11b1 class II 0.55105 (3.6104) 0.20105 (0.17104) 2.0105 (2.8104) 0.86105 (2.4104)
CD11b1 class II1 1.4105 (5.2104) 1.4105 (4.7104) 0.068105 (0.34104) 0.12105 (0.048104)
CD11b1 LyG1 7/41 b) 0.35105 (2.4104) 0.064105 (0.096104) 1.4105(0.77104) 0.46105 (0.43104)
CD41 0.60105 (2.1104) 0.83105 (5.8104) 0.24105 (0.096104) 0.31105 (0.48104)
B2201 0.038105 (0.21104) 0.044105 (0.032104) 0.019105 (0.10104) 0.019105 (0.092104)
a) Two to four experiments/group, with four to seven mice/experiment, giving a minimum total, n 5 8 mice per group. Standard deviations are
shown in parenthesis.
b) This population is also Ly6C intermediate and class II negative.
Table 2. Relative mRNA expressiona)
Wt-Wt Wt-IL-17R/ IFN-g/-Wt IFN-g/-IL-17R/
IL-1b 517.5 191.3 246.3 816.3
IL-1f9 11.5 2.40 21.3 66.1
GM-CSF 104.5 115.7 81.30 450.4
CCL22 3.30 3.95 6.23 20.7
CCL17 17.2 19.5 9.80 68.8
CXCL9 5700 9433 24.60 394.7
CXCR2 3.80 1.10 17.6 28.9
CD74 507.7 512.1 10.40 83.30
CXCL1 81.0 46.8 134 47.5
CXCL2 2008 920.7 964.1 273.3
a) Fold induction over naı̈ve spinal cords, normalized to GAPDH, Hprt1, and b actin.
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cytometric analyses demonstrated that the anti-CXCR2 treatments
depleted neutrophils from the blood and spleen, but spared other
leukocyte subsets (data not shown). EAE was completely abrogated
in anti-CXCR2-treated hosts (Fig. 4E), demonstrating the impor-
tance of neutrophils in the non-Th1/Th17 model of EAE.
Discussion
Drugs that neutralize T-cell-derived cytokines have been proposed
as putative therapies for autoimmune disease. Our findings suggest
that the emergence of redundant immunopathogenic pathways
could undermine such a strategy in MS. In this article, we
demonstrate that autoimmune demyelination can occur in the
combined absence of both IFN-g and IL-17. By extension,
autoreactive T cells other than those that fall within the classic
Th1 and Th17 lineages are capable of mediating CNS autoimmu-
nity. Th9 cells were recently heralded as a novel encephalitogenic
subset [23]. However, the IL-12-stimulated IFN-g/ T cells used
in our studies did not secrete IL-9, nor was IL-9 detectable in the
CNS of the host mice into which they were injected (unpublished
data). We found that disease induction in our model is dependent
on GM-CSF, and that CD41 T cells were the primary source of this
mediator in the inflamed CNS. This suggests that the MOG-specific
donor T cells produced GM-CSF themselves and/or induced its
production in bystander host T cells. Hence, myelin-specific
Figure 4. EAE induced via an IFN-g/IL-17-independent pathway is GM-CSF dependent. MOG35–55/CFA-primed lymph node cells were harvested
from IFN-g/ mice and cultured with antigen and IL-12 prior to adoptive transfer into IL-17RA/ hosts. (A) Clinical scores of recipient mice that
were treated with the IL-1R antagonist, Anakinra, or vehicle daily from day 0 to day 10 post-transfer (2.5 mg/dose). (B) Supernatants were collected
from the lymph node cell cultures every 24 h prior to adoptive transfer. GM-CSF levels were measured by ELISA. (C) Mononuclear cells were isolated
from the spinal cords of IL-17R/mice at peak EAE following the adoptive transfer of MOG-specific, IFN-g/ CD41 T cells. GM-CSF expression was
assessed by intracellular staining and flow cytometry. Dot plots (GM-CSF stain, middle; rIgG2a isotype, right) are gated on blasting lymphocytes (left).
About 83% of GM-CSF-producing cells were CD41CD31, irrespective of the gate used (data not shown) (D, E) Mice were treated with (D) GM-CSF-
neutralizing monoclonal antibodies or (E) anti-serum to CXCR2 from day 0 to day 10 post-transfer. Anti-GM-CSF (0.5 mg/dose) and CXCR2 anti-
serum (0.5 mL/dose) were administered every other day. For all in vivo experiments, each treatment group contained eight to ten mice. Disease
incidence is shown at the right-hand side of the relevant symbol. The data shown are representative of two or more experiments with similar
results. po0.01, po0.05, compared with the control group.
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T cells with a diverse array of cytokine profiles have encephalito-
genic potential. In some forms of EAE, one cell type might
predominate. In others, cells of multiple phenotypes might
contribute to CNS injury in an additive or synergistic manner. A
common downstream mediator that is critical for demyelination
has yet to be identified.
It was previously reported that C57BL/6 mice deficient in GM-
CSF or GM-CSF receptor are resistant to EAE induced by active
immunization with MOG peptide [24–26]. GM-CSF could, theo-
retically, foster inflammation in the CNS by stimulating local
and/or infiltrating APC to upregulate MHC class II and costimu-
latory molecules. There is also evidence that GM-CSF can trigger
IL-6 production by dendritic cells, and hence enhance survival of
autoreactive T cells [27]. In addition, we have found that GM-
CSF facilitates the mobilization of classII–/loLy6Chi bone marrow
cells in MOG-immunized mice [24]. These immature myeloid
cells ultimately accumulate in the CNS and differentiate into
dendritic cells. However, as with IL-17, a requirement for GM-
CSF is not universal across all EAE models. For example, EAE
triggered by the adoptive transfer of PLP-specific Th1 cells in SJL
mice is GM-CSF independent [28]. In that model, IFN-g
production by donor T cells results in upregulation of ELR– CXC
chemokines and the recruitment of classIIhi CD11b1 monocytes
to the CNS. This could obviate the requirement for GM-CSF for
the establishment of a local population of activated APC.
The fact that depletion of CXCR21 cells suppressed EAE
substantiates a nonredundant role for neutrophils in our model.
It is likely that this intervention will be most beneficial in EAE
mediated by IFN-g/ effectors, since neutrophils are sparse in
CNS infiltrates induced by WT T cells [29]. Our data also suggest
that neutrophils may contribute significantly to atypical EAE,
since the percentage and absolute number of neutrophils in the
CNS of WT hosts injected with IFN-g/ effector cells was
remarkably elevated (Fig. 2E and 3B). Neutrophils mediate
blood–brain barrier breakdown in animal models of viral ence-
phalitis and following intracerebral injection of IL-1b [30, 31].
We speculate that depletion of neutrophils prevents the increased
blood–brain barrier permeability that ordinarily heralds the onset
of clinical EAE. Other plausible mechanisms of action of neutro-
phils include altering the cytokine/chemokine milieu in the CNS
microenvironment and facilitating the mobilization of myeloid
cell precursors from the bone marrow.
This study provides further evidence that IL-12 is a powerful
inducer of encephalitogenicity in CD41 T cells, and that this
function is independent of IFN-g as well as IL-17A/F. It remains
unclear why IL-12 does not compensate for IL-23 deficiency in
MOG35–55-immunized IL-23p19
/ C57BL/6 mice. One explana-
tion is that the conditions used for active immunization (i.e.
subcutaneous administration of antigen in CFA and systemic
administration of Bordetella pertussis toxin) are more effective in
stimulating IL-23, than IL-12, production by the APC that prime
myelin-reactive T cells in vivo [32]. On the other hand, IL-23 has
been shown to restrain regulatory T-cell populations in a colitis
model [33], raising the possibility that p19/ mice have a more
robust regulatory T-cell compartment and are generally more
resistant to autoimmunity on that basis. Similarly, a contributing
factor to the susceptibility of IL-12 p35-deficient mice to EAE may
be the absence of the regulatory cytokine IL-35, which shares the
p35 subunit with IL-12 [34]. Our system avoids these complicating
factors by analyzing the direct effects of IL-12 on the encephalito-
genic properties myelin-specific CD41 T cells ex vivo. The
mechanism by which IL-12 promotes the encephalitogenicity of
IFN-g/ effector cells remains to be elucidated.
We have previously shown that myelin-reactive Th1 and Th17
cells evoke distinct cytokine and chemokine pathways to induce
inflammatory demyelinating disease with a similar clinical
presentation [28]. Here, we expand this concept further by show-
ing that conventional EAE can also be mediated by a non-IFN-g/IL-
17 effector pathway. Similarly, MS likely represents a hetero-
geneous group of diseases, mediated by distinct cytokine pathways,
with a common clinical endpoint. In support of this contention,
analysis of brain specimens has demonstrated that MS can be
classified into at least four subtypes based on distinctive histo-
pathological features [35]. Furthermore, MS patients exhibit
diverse responses to specific immunomodulatory interventions. In
order to achieve optimal control over disease, in the future it might
be necessary to stratify patients based on their immunological
profiles and customize treatment accordingly.
Materials and methods
Mice
Briefly, 8- to 12-wk-old WT and IFN-g-deficient C57BL/6 mice were
obtained from NCI Frederick (Frederick, MD, USA) and The
Jackson Laboratory (Bar Harbor, ME, USA), respectively, and
housed in microisolator cages. All animal protocols were approved
by the University Committee on Use and Care of Animals.
Immunization and T-cell culture
Mice were injected subcutaneously with 100 mg MOG35–55
MEVGWYRSP-FSRVVHLYRNGK (Biosynthesis, Lewisville, TX,
USA) in complete Freund’s adjuvant (Difco, Detroit, MI, USA).
Draining lymph nodes were harvested 12–14 days post-immuni-
zation, pooled, and passed through a 70-mm cell strainer (BD
Falcon, Franklin Lakes, NJ, USA). Lymph node cells were
cultured in vitro for 4 days with MOG35–55 under conditions
favorable to the generation of Th1 cells (rmIL-12, 5 ng/mL;
rmIFN-g, 2 ng/mL; anti-IL-4 (clone 11B11), 10 mg/mL).
Induction and treatment of EAE
After 4 day in vitro culture, lymph node cells were collected and
CD41 T cells were purified using negative selection columns
(Cedarlane) to a purity of 88–95%, confirmed by flow cytometry. In
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total, 5–6 106 CD41 T cells were injected intraperitoneally in
sterile PBS, and mice were observed daily for signs of EAE.
Those with conventional EAE were scored as described previously
[29]. For atypical EAE, the following scale was used: 0, asympto-
matic; 1, slight listing/difficulty righting; 2, obvious imbalance but
able to ambulate; 3, severely impaired balance/ambulation; and 4,
incapacitated due to inability to maintain upright posture/spinning.
Mean clinical scores were compared using the Student’s t-test.
Antibodies used for in vivo neutralization were anti-GM-CSF
(clone 22E9.11) and anti-IFN-g (clone XMG1.2). Polyclonal
rabbit anti-serum against IL-13 and CXCR2 were provided by Dr.
Nicholas Lukacs and Dr. Thomas Lane, respectively. Rat IgG was
used as a control for monoclonal antibody treatments, and
normal rabbit serum (Sigma-Aldrich, St. Louis, MO, USA) was
used as a control for the IL-13 and CXCR2 anti-sera. The IL-1R
antagonist Anakinra was purchased from commercial sources. All
treatments were given intraperitoneally.
Quantitative RT-PCR
RT-PCR was done using 384-well mouse ‘‘inflammatory response
and autoimmunity’’ PCR arrays (SA Biosciences, Frederick, MD,
USA). Arrays were performed on individual mice (three mice/
group) and genes of interest were confirmed independently by
quantitative RT-PCR (five to eight mice/group). Whole spinal cords
were homogenized in Trizol reagent (Invitrogen, Carlsbad, CA,
USA) and RNA was isolated by phenol/chloroform extraction.
Genomic DNA was removed by Turbo DNase (Ambion, Foster City,
CA, USA) and purity of RNA was confirmed by a ratio of
A260:A280. cDNA was synthesized using a RT2 First Strand kit
(SA Biosciences). Data were normalized to GAPDH, HPRT1, and b
actin, and are shown as fold increase over naı̈ve spinal cords.
Flow cytometry
Spinal cords were harvested at peak disease and incubated with
DNase (1 mg/mL) and collagenase (2 mg/mL) for 1 h at 371C.
Mononuclear cells were isolated over a 30/70% Percoll gradient
(GE Healthcare, Piscataway, NJ, USA). Flow cytometry was
performed using a BD Facs Canto.
Histological staining
After perfusion, spinal cords were fixed in 10% formalin,
sectioned, and stained with hematoxylin and eosin using
standard protocols [29].
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